|
|
|
|
|
05.11.25 - 22:03
|
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
|
|
|
Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for GalapagosContinued evolution of leadership team aligned with strategic directionRobust balance sheet with €3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025 cash position expected at €2.975 billion to €3.025 billion Management to host a conference call tomorrow, November 6, 2025, at 14:00 CET / 08:00 AM ET Mechelen, Belgium; November 5, 2025, 22:01 CET; regulated information – Galapagos NV (Euronext & Nasdaq: GLPG) today announced its financial results for the first nine months of 2025, and provided a third quarter and recent business update. “We successfully delivered on our commitment to define a clear path forward for Galapagos following the completion of the strategic review of our cell therapy business,” said Henry Gosebruch, CEO of Galapagos. “We have built a te...
|
|
|
|
|
31.10.25 - 08:30
|
Oncoinvent appoints Dr. Ramzi Amri as new CFO (Cision)
|
|
|
Oncoinvent ASA (OSE: ONCIN) today announces the appointment of Dr. Ramzi Amri, M.D., Ph.D. as Chief Financial Officer (CFO), effective on or around 15 January.
Dr. Amri succeeds Tore Kvam, who has served as CFO since 2019. The company would like to thank Mr Kvam for his valuable work and dedication over the past years. “During his seven years in Oncoinvent, Tore Kvam has worked tirelessly to contribute to Oncoinvent's development and performance. We're very grateful for his contribution,” says Øystein Soug, CEO of Oncoinvent.
Dr. Amri joins Oncoinvent from Galapagos NV, where he...
|
|
|
|
|
23.10.25 - 22:03
|
Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors (GlobeNewswire EN)
|
|
|
Mechelen, Belgium; October 23, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present new in vitro pharmacological data from its selective TYK2 inhibitor, GLPG3667, currently in two Phase 3-enabling studies in dermatomyositis (DM) and systemic lupus erythematosus (SLE), at the American College of Rheumatology (ACR) Convergence 2025, taking place in Chicago, IL, October 24-29, 2025....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
